Three citizens of China entered into an agreement to acquire Chongqing Zhuoda Pharmaceutical Co, Ltd. from BIMI International Medical, Inc. (NasdaqCM:BIMI) on October 24, 2022. The closing of the Agreement is expected to take place late in the fourth quarter of 2022, subject to necessary regulatory approvals.